Hydroxyurea

In this video, Ronak Mistry, DO, discusses the results of a study presented at ASH Annual Meeting that examined the use of hydroxyurea in patients with hemoglobin SC disease.

SAN DIEGO — Hydroxyurea conferred benefit to children and adults with hemoglobin SC disease, according to study results presented at ASH Annual Meeting and Exposition.

Hydroxyurea did not affect ovarian reserve among girls and young women with sickle cell disease, according to results published in Blood Advances.

Nearly three-quarters of individuals with sickle cell disease are not using disease-modifying therapies in their treatment, according to a study published in JAMA Network Open.

SAN DIEGO — Guideline-directed use of hydroxyurea may reduce cerebrovascular disease among individuals with sickle cell disease, according to single-center study results.

Despite having been established as the primary disease-modifying therapy for individuals with sickle cell anemia, hydroxyurea remains underused among children with the disease, according to data published in JAMA Network Open.

Despite the severe pain and mortality risk associated with sickle cell anemia, few children undergo the recommended screening and treatment for this condition and its complications, according to a CDC report.

In this video, Aaron T. Gerds, MD, MS, discusses critical takeaways from the REVEAL study presented at ASH Annual Meeting and Exposition.

Toxicity on spermatogenesis may not be a major concern for boys with severe sickle cell disease who require hydroxyurea treatment before puberty, according to results of a study published in Blood.

Escalated dosing of hydroxyurea had greater clinical efficacy than fixed dosing of the drug for children with sickle cell disease in sub-Saharan Africa, according to randomized study results published in The New England Journal of Medicine.